Skip to content
Research/Immune Modulation/Delgocitinib

Delgocitinib

Delgocitinib is a Janus kinase (JAK) inhibitor primarily used for its immunomodulatory effects, particularly in treating inflammatory skin conditions like atopic dermatitis. By inhibiting JAK pathways, it reduces inflammation and immune response, which is crucial for managing chronic inflammatory conditions that can impact longevity and overall health.

Intelligence Profile

Clinical Applications

Clinical Applications of Delgocitinib

Delgocitinib is primarily used for treating dermatological conditions such as atopic dermatitis and chronic hand eczema. Its efficacy has been evaluated in several clinical trials and case reports:

  1. Atopic Dermatitis: An 8-week randomized Phase IIb trial demonstrated a dose-dependent improvement in adults with mild to severe atopic dermatitis when using a cream formulation of delgocitinib. This study supports its potential as a therapeutic option for this condition (The British Journal of Dermatology, 2026).

  2. Chronic Hand Eczema: Delgocitinib has been studied extensively for chronic hand eczema. A Phase 2b trial over 16 weeks assessed various dosages, showing positive outcomes in the management of moderate to severe cases (Expert Opinion on Pharmacotherapy, 2026). Additionally, real-world evidence supports its effectiveness and improvement in quality of life for patients with chronic hand eczema (Dermatitis, 2026).

  3. Vulvar Lichen Sclerosus: In a case report, delgocitinib cream was used for refractory vulvar lichen sclerosus, suggesting it may be beneficial where other treatments have failed (JAAD Case Reports, 2026).

  4. Frontal Fibrosing Alopecia: A completed Phase II trial evaluated its effects on the molecular signature and efficacy in adults with frontal fibrosing alopecia, though specific results from this study are not detailed in the provided evidence.

  5. Pediatric Atopic Dermatitis: A systematic review focused on topical Janus Kinase inhibitors, including delgocitinib, highlighted potential benefits for pediatric atopic dermatitis, indicating an area under investigation (Pediatric Dermatology, 2026).

It is noteworthy that ongoing and completed trials are exploring additional uses and confirming the safety profile of delgocitinib in various dermatological conditions.

Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for medical care and treatment.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.